Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $0.34.

  • Indivior Pharmaceuticals' EPS (Basic) rose 11250.0% to $0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.03, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of $0.05 for FY2024, which is 10543.48% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' EPS (Basic) is $0.34, which was up 11250.0% from $0.15 recorded in Q2 2025.
  • Indivior Pharmaceuticals' EPS (Basic)'s 5-year high stood at $225.0 million during Q1 2023, with a 5-year trough of -$231.6 million in Q3 2023.
  • Moreover, its 4-year median value for EPS (Basic) was $0.36 (2025), whereas its average is $13.5 million.
  • Within the past 5 years, the most significant YoY rise in Indivior Pharmaceuticals' EPS (Basic) was 12097.04% (2023), while the steepest drop was 42152.0% (2023).
  • Indivior Pharmaceuticals' EPS (Basic) (Quarter) stood at -$2.37 in 2022, then surged by 120.97% to $0.5 in 2023, then crashed by 67.76% to $0.16 in 2024, then soared by 112.5% to $0.34 in 2025.
  • Its EPS (Basic) was $0.34 in Q3 2025, compared to $0.15 in Q2 2025 and $0.38 in Q1 2025.